Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' ALBANELL J' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 34 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Bellmunt, J; de Wit, R; Albanell, J; Baselga, J
      A feasibility study of carboplatin with fixed dose of gemcitabine in 'unfit' patients with advanced bladder cancer

      EUROPEAN JOURNAL OF CANCER
    2. Baselga, J; Albanell, J
      Mechanism of action of anti-HER2 monoclonal antibodies

      ANNALS OF ONCOLOGY
    3. Baselga, J; Albanell, J; Molina, MA; Arribas, J
      Mechanism of action of trastuzumab and scientific update

      SEMINARS IN ONCOLOGY
    4. Albanell, J; Rojo, F; Baselga, J
      Pharmacodynamic studies with the epidermal growth factor receptor tyrosinekinase inhibitor ZD1839

      SEMINARS IN ONCOLOGY
    5. Albanell, J; Codony-Servat, J; Rojo, F; Del Campo, JM; Sauleda, S; Anido, J; Raspall, G; Giralt, J; Rosello, J; Nicholson, RI; Mendelsohn, J; Baselga, J
      Activated extracellular signal-regulated kinases: Association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments

      CANCER RESEARCH
    6. Molina, MA; Codony-Servat, J; Albanell, J; Rojo, F; Arribas, J; Baselga, J
      Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells

      CANCER RESEARCH
    7. Bellmunt, J; Guillem, V; Paz-Ares, L; Gonzalez-Larriba, JL; Carles, J; Albanell, J; Tabernero, JM; Cortes-Funes, H; Baselga, J
      Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer

      EUROPEAN JOURNAL OF CANCER
    8. Bellmunt, J; Guillem, V; Paz-Ares, L; Gonzalez-Larriba, JL; Carles, J; Batiste-Alentorn, E; Saenz, A; Lopez-Brea, M; Font, A; Nogue, M; Bastus, R; Climent, MA; de la Cruz, JJ; Albanell, J; Banus, JM; Gallardo, E; Diaz-Rubio, E; Cortes-Funes, H; Baselga, J
      Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium

      JOURNAL OF CLINICAL ONCOLOGY
    9. Albanell, J; Baselga, J
      Systemic therapy emergencies

      SEMINARS IN ONCOLOGY
    10. Albanell, J; Baselga, J
      The ErbB receptors as targets for breast cancer therapy

      JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
    11. Albanell, J; Baselga, J
      Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer

      DRUGS OF TODAY
    12. Baselga, J; Norton, L; Albanell, J; Kim, YM; Mendelsohn, J
      Recombinant humanized anti-HER2 antibody (Herceptin (TM)) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts (vol 58, pg 2825, 1998)

      CANCER RESEARCH
    13. Codony-Servat, J; Albanell, J; Lopez-Talavera, JC; Arribas, J; Baselga, J
      Cleavage of the HER2 ectodomain is a pervanadate-activable process that isinhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells

      CANCER RESEARCH
    14. Albanell, J; Bosl, GJ; Reuter, VE; Engelhardt, M; Franco, S; Moore, MAS; Dmitrovsky, E
      Telomerase activity in germ cell cancers and mature teratomas

      JOURNAL OF THE NATIONAL CANCER INSTITUTE
    15. BASELGA J; NORTON L; ALBANELL J; KIM YM; MENDELSOHN J
      RECOMBINANT HUMANIZED ANTI-HER2 ANTIBODY (HERCEPTIN(TM)) ENHANCES THEANTITUMOR-ACTIVITY OF PACLITAXEL AND DOXORUBICIN AGAINST HER2 NEU OVEREXPRESSING HUMAN BREAST-CANCER XENOGRAFTS/

      Cancer research
    16. RIBAS A; ALBANELL J; SOLECALVO LA; GALLARDO E; BELLMUNT J; VERA R; VIDAL R; CARULLA J; BASELGA J
      CYCLOPHOSPHAMIDE, METHOTREXATE, AND CHRONIC ORAL TEGAFUR MODULATED BYFOLINIC ACID IN THE TREATMENT OF PATIENTS WITH ADVANCED BREAST-CARCINOMA

      Cancer
    17. BOS M; MENDELSOHN J; KIM YM; ALBANELL J; FRY DW; BASELGA J
      PD153035, A TYROSINE KINASE INHIBITOR, PREVENTS EPIDERMAL GROWTH-FACTOR RECEPTOR ACTIVATION AND INHIBITS GROWTH OF CANCER-CELLS IN A RECEPTOR NUMBER-DEPENDENT MANNER

      Clinical cancer research
    18. ENGELHARDT M; ALBANELL J; DRULLINSKY P; HAN W; GUILLEM J; SCHER HI; REUTER V; MOORE MAS
      RELATIVE CONTRIBUTION OF NORMAL AND NEOPLASTIC-CELLS DETERMINES TELOMERASE ACTIVITY AND TELOMERE LENGTH IN PRIMARY CANCERS OF THE PROSTATE,COLON, AND SARCOMA

      Clinical cancer research
    19. REICHMAN TW; ALBANELL J; WANG XN; MOORE MAS; STUDZINSKI GP
      DOWN-REGULATION OF TELOMERASE ACTIVITY IN HL60 CELLS BY DIFFERENTIATING AGENTS IS ACCOMPANIED BY INCREASED EXPRESSION OF TELOMERASE-ASSOCIATED PROTEIN

      Journal of cellular biochemistry
    20. BELLMUT J; ERES N; RIBAS A; CASADO S; ALBANELL J; BASELGA J
      FEASIBILITY TRIAL OF HIGH-DOSE 7-DAY CONTINUOUS-INFUSION IFOSFAMIDE GIVEN ON AN OUTPATIENT BASIS

      Cancer chemotherapy and pharmacology
    21. NASONBURCHENAL K; MAERZ W; ALBANELL J; ALLOPENNA J; MARTIN P; MOORE MAS; DMITROVSKY E
      COMMON DEFECTS OF DIFFERENT RETINOIC ACID-RESISTANT PROMYELOCYTIC LEUKEMIA-CELLS ARE PERSISTENT TELOMERASE ACTIVITY AND NUCLEAR-BODY DISORGANIZATION

      Differentiation
    22. RIBAS A; ALBANELL J; BELLMUNT J; BERMEJO B; GALLARDO E; VERA R; BODI R; SOLECALVO LA
      FREQUENT DOSE DELAYS AND GROWTH-FACTOR REQUIREMENTS WITH THE SEQUENTIAL DOXORUBICIN-CMF SCHEDULE

      Acta oncologica
    23. BELLMUNT J; RIBAS A; ERES N; ALBANELL J; ALMANZA C; BERMEJO B; SOLE LA; BASELGA J
      CARBOPLATIN-BASED VERSUS CISPLATIN-BASED CHEMOTHERAPY IN THE TREATMENT OF SURGICALLY INCURABLE ADVANCED BLADDER-CARCINOMA

      Cancer
    24. ENGELHARDT M; KUMAR R; ALBANELL J; PETTENGELL R; HAN W; MOORE MAS
      TELOMERASE REGULATION, CELL-CYCLE, AND TELOMERE STABILITY IN PRIMITIVE HEMATOPOIETIC-CELLS

      Blood
    25. RIBAS A; ALBANELL J; BELLMUNT J; SOLECALVO LA
      ADVERSE EFFECT ON BONE-MARROW PROTECTION OF PRECHEMOTHERAPY GRANULOCYTE-COLONY-STIMULATING FACTOR SUPPORT

      Journal of the National Cancer Institute
    26. ALBANELL J; LONARDO F; RUSCH V; ENGELHARDT M; LANGENFELD J; HAN W; KLIMSTRA D; VENKATRAMAN E; MOORE MAS; DMITROVSKY E
      HIGH TELOMERASE ACTIVITY IN PRIMARY LUNG CANCERS - ASSOCIATION WITH INCREASED CELL-PROLIFERATION RATES AND ADVANCED PATHOLOGICAL STAGE

      Journal of the National Cancer Institute
    27. RIBAS A; ALBANELL J; BELLMUNT J; SOLECALVO LA; BERMEJO B; GALLARDO E; VIDAL R; VERA R; ERES N; CARULLA J; BASELGA J
      5-DAY COURSE OF GRANULOCYTE-COLONY-STIMULATING FACTOR IN PATIENTS WITH PROLONGED NEUTROPENIA AFTER ADJUVANT CHEMOTHERAPY FOR BREAST-CANCER IS A SAFE AND COST-EFFECTIVE SCHEDULE TO MAINTAIN DOSE-INTENSITY

      Journal of clinical oncology
    28. RIBAS A; BELLMUNT J; ALBANELL J; DETORRES I; BERMEJO B; DETORRES JA; MOROTE J; GALLARDO E; VERA R; CARULLA J; SOLECALVO LA
      EARLY RESULTS OF THE VALUE OF P53 IN PREDICTING SURVIVAL IN A HOMOGENEOUS COHORT OF PATIENTS WITH INVASIVE BLADDER-CANCER TREATED WITH A NEOADJUVANT CARBOPLATIN-BASED REGIMEN (M-CAVI)

      Tumori
    29. BELLMUNT J; RIBAS A; ALBANELL J; BERMEJO B; VERA R; DETORRES JA; MOROTE J; LOPEZPACIOS MA; MANUS JM; ROVIROSA A; CARULLA J; SOLE LA
      M-CAVI, A NEOADJUVANT CARBOPLATIN-BASED REGIMEN FOR THE TREATMENT OF T2-4NOMO CARCINOMA OF THE BLADDER

      American journal of clinical oncology
    30. ALBANELL J; HAN W; MELLADO B; GUNAWARDANE R; SCHER HI; DMITROVSKY E; MOORE MAS
      TELOMERASE ACTIVITY IS REPRESSED DURING DIFFERENTIATION OF MATURATION-SENSITIVE BUT NOT RESISTANT HUMAN TUMOR-CELL LINES

      Cancer research
    31. ENGELHARDT M; ALBANELL J; KUMAR R; HAN W; MOORE MAS
      TELOMERASE UP-REGULATION AND TELOMERE LENGTH IN EX-VIVO EXPANSION CULTURES OF HEMATOPOIETIC PROGENITOR CELLS

      Blood
    32. BELLMUNT J; RIBAS A; CASADO S; ALBANELL J; CARULLA J; SOLE LA
      HIGH-DOSE CONTINUOUS-INFUSION (CI) IFOSFAMIDE WITHOUT HEMATOPOIETIC SUPPORT IN HEAVILY PRETREATED BREAST-CANCER (BC) AND SARCOMA (S) PATIENTS

      European journal of cancer
    33. RIBAS A; BELLMUNT J; ALBANELL J; CAPDEVILA JA; OCANA I; GALLEGO OS; MALDONADO J; GIRALT J; SOLE LA
      MALIGNANT LYMPHOPROLIFERATIVE-DISEASES IN HIV-SEROPOSITIVE PATIENTS -A STUDY OF 40 CASES AT A SINGLE INSTITUTION IN SPAIN

      Acta oncologica
    34. SOLE LA; ALBANELL J; BELLMUNT J; RIBAS A; GALLEGO OS; CARULLA J
      PHASE-II TRIAL OF AN ALL-ORAL REGIMEN OF TEGAFUR AND FOLINIC ACID IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC BREAST-CANCER

      Cancer


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 16/01/21 alle ore 13:22:38